Holen Sie sich die Stockscreener-App
26.95
0.65%
-0.175
Schlusskurs vom Vortag:
$27.12
Offen:
$27.4
24-Stunden-Volumen:
86,546
Relative Volume:
0.42
Marktkapitalisierung:
$336.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.74M
KGV:
-6.0631
EPS:
-4.4441
Netto-Cashflow:
$-44.57M
1W Leistung:
-6.31%
1M Leistung:
-16.09%
6M Leistung:
+155.16%
1J Leistung:
+349.08%
1-Tages-Spanne:
$26.50
$28.12
1-Wochen-Bereich:
$26.00
$30.60
52-Wochen-Spanne:
$4.90
$35.62
Forte Biosciences Inc Stock (FBRX) Company Profile
Firmenname
Forte Biosciences Inc
Sektor
Branche
Telefon
(310) 618-6994
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
26.90 | 339.73M | 0 | -51.74M | -44.57M | -4.4441 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.01 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.43 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.48 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-18 | Eingeleitet | Guggenheim | Buy |
| 2025-01-21 | Eingeleitet | TD Cowen | Buy |
| 2024-04-08 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Hochstufung | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Herabstufung | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Herabstufung | Truist | Buy → Hold |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-26 | Eingeleitet | Citigroup | Buy |
| 2020-08-28 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Eingeleitet | Truist | Buy |
Alle ansehen
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
History Review: Can Forte Biosciences Inc maintain its current growth rateGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Bank Watch: Can LOKV lead its sector in growth2025 Support & Resistance & Momentum Based Trading Ideas - baoquankhu1.vn
Can Forte Biosciences Inc. stock beat analyst upgradesEarnings Beat & Growth Focused Stock Pick Reports - Naître et grandir
Can Forte Biosciences Inc. stock maintain growth trajectoryWeekly Loss Report & Technical Confirmation Alerts - Naître et grandir
Portfolio Update: Can MKTW withstand a market correction2025 Analyst Calls & Community Verified Trade Alerts - baoquankhu1.vn
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules - marketscreener.com
Vitiligo Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Stock Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Biotech Forte Biosciences hands 100,000 stock options to new hires - Stock Titan
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
(FBRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBRX PE Ratio & Valuation, Is FBRX Overvalued - Intellectia AI
Forte Biosciences (FBRX) Raised to Buy: Key Information You Need - Bitget
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Pullback Watch: Is Forte Biosciences Inc a top pick in the sector2025 Risk Factors & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Forte Biosciences Inc. a top pick in the sectorWeekly Stock Summary & Weekly Watchlist for Hot Stocks - mfd.ru
Will Forte Biosciences Inc. benefit from rate cutsQuarterly Portfolio Report & Stepwise Swing Trade Plans - mfd.ru
Price-Driven Insight from (FBRX) for Rule-Based Strategy - Stock Traders Daily
Stock Traders Purchase Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Analyst Downgrade: Is Forte Biosciences Inc stock a good dividend stockCEO Change & Growth Focused Entry Reports - baoquankhu1.vn
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth - Yahoo Finance
Celiac Disease Clinical Trial Pipeline Gains Momentum as 25+ - openPR.com
Growth Recap: How much upside does KWESST Micro Systems Inc Equity Warrant havePortfolio Performance Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Why Forte Biosciences Inc. stock is popular among millennialsJuly 2025 Reactions & Daily Profit Maximizing Tips - mfd.ru
Forte Biosciences, Inc. (NASDAQ:FBRX) Sees Large Decrease in Short Interest - MarketBeat
Why Airbnb Inc. stock is favored by top institutionsJuly 2025 Institutional & Reliable Price Breakout Alerts - mfd.ru
Celiac Disease Clinical Trial Pipeline Gains Momentum As 25+ Companies Advance Novel Therapies Toward Market Entry: Delveinsight Teva Pharmaceutical Industries, Barinthus Biotherapeutics, Topas - Menafn.com
Will Forte Biosciences Inc. stock deliver better than expected guidanceQuarterly Earnings Report & Proven Capital Preservation Tips - mfd.ru
Is Forte Biosciences Inc. stock a good choice for value investors2025 Technical Patterns & AI Forecast for Swing Trade Picks - mfd.ru
Can Forte Biosciences Inc. maintain its current growth rateDollar Strength & AI Powered Buy/Sell Recommendations - mfd.ru
Institutional Owners May Ignore Forte Biosciences, Inc.'s (NASDAQ:FBRX) Recent US$87m Market Cap Decline as Longer-term Profits Stay in the Green - 富途牛牛
Does Forte Biosciences Inc. have pricing powerPortfolio Performance Summary & Growth Focused Stock Pick Reports - mfd.ru
Layoff Watch: Is Forte Biosciences Inc being accumulated by smart moneyJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - marketscreener.com
Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan
Forte Biosciences Insider Ups Holding By 30% During Year - simplywall.st
Aug Outlook: Will BEAM stock recover after earningsWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
(FBRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Dow Update: Will Forte Biosciences Inc announce a stock splitWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5% - MarketBeat
Federated Hermes Inc. Acquires 563,147 Shares of Forte Biosciences, Inc. $FBRX - MarketBeat
Celiac Disease Pipeline 2025: FDA Updates, Therapy - openPR.com
(FBRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Celiac Disease Clinical Trial Pipeline Gains Momentum: 25+ - openPR.com
Trend Recap: Can META stock outperform in a bear marketTrade Volume Summary & AI Forecast Swing Trade Picks - baoquankhu1.vn
US Market Recap: What is the earnings history of Jupiter Neurosciences Inc2025 Stock Rankings & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Is Forte Biosciences Inc. stock oversold or undervaluedJuly 2025 Sector Moves & Real-Time Volume Triggers - Bollywood Helpline
Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Forte Biosciences Inc-Aktie (FBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):